Kairos Pharma, Ltd. KAPA
0.49 USD -0.02 (-3.03%)
Nov 4, 2026, 3:58 PM EST
0.4897 Day range 0.5298
0.418 52-week range 7.28
- YTD
- -90.15%
- 1 year
- -91.93%
Financial health
Altman Z-Score
-5.20 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 3
Valuation
P/E -2.4×
FY 2020 5y median -15.3× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.1×
FY 2020 5y median -13.0× FY 2025
P/FCF -3.8×
FY 2020 5y median -4.4× FY 2025
EV/EBITDA -1.6×
FY 2020 5y median -17.7× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -26.3%
FY 2020 5y median -1.3% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -85.9%
FY 2020 5y median 87.2% FY 2025
ROIC -87.9%
FY 2020 5y median 96.3% FY 2025
ROA -83.3%
FY 2020 5y median -101.4% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -137.8%
FY 2020 FY 2025
EPS (diluted) -30.4%
FY 2020 FY 2025
Free Cash Flow 13.0%
FY 2020 FY 2025
Financial Health
Current Ratio 27.1×
FY 2020 5y median 0.3× FY 2025
Quick Ratio 27.1×
FY 2020 5y median 0.3× FY 2025
Debt / Equity 0.0×
FY 2020 5y median -0.3× FY 2025
Net Debt / EBITDA 0.8×
FY 2020 5y median -0.2× FY 2025
Interest Coverage 0.0×
FY 2020 5y median -2.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31